Product Images Cosentyx
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 48 images provide visual information about the product associated with Cosentyx NDC 0078-0639 by Novartis Pharmaceuticals Corporation, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
PRINCIPAL DISPLAY PANEL NDC 0078-0639-97 Cosentyx® (secukinumab) Injection Single-use Prefilled Syringe 150 mg/mL 1 Prefilled Syringe ATTENTION: Dispense with enclosed Medication Guide. For Subcutaneous Use Only Sterile Solution - Contains No Preservative Caution: Contains Natural Rubber Latex Which May Cause Allergic Reaction. Rx only NOVARTIS - cosentyx 01
This is a description of Cosentyx medication, which is used for subcutaneous injection. The medication comes in the form of a single-dose prefilled syringe containing 150 mg of secukinumab, and should be stored in a refrigerator at a temperature of 2-8°C (36-46°F). The medication can be stored at room temperature for up to 0-30°C (86°F) for a maximum of 4 days, after which it should be discarded. The medication guide enclosed should be followed while dispensing the medication. The medication may contain Latex which may cause an allergic reaction. For more information, visit the Cosentyx official website or call 1-835 NOW-1IOVA (-888-860-6622).*
Figure A - cosentyx 02
Figure B - cosentyx 03
Figure C - cosentyx 04
Figure D - cosentyx 05
Figure E - cosentyx 06
Figure F - cosentyx 07
COSENTYX prefilled syringe parts (see Figure A): - cosentyx 08
This appears to be a description of a syringe with various features such as finger grips, a needle cap, a viewing window, label & expiration date, guard wings and plunger head. It is likely a medical device used for injecting medication or other substances.*
Figure B - cosentyx 09
Figure C - cosentyx 10
Figure D - cosentyx 11
Figure E - cosentyx 12
Figure F - cosentyx 13
Figure G - cosentyx 14
Figure H - cosentyx 15
Figure I - cosentyx 16
Figure J - cosentyx 17
Figure A - cosentyx 18
This text describes the features of a needle that includes a needle guard, cap, viewing window, and internal needle cover.*
Figure B - cosentyx 19
Figure C - cosentyx 20
Figure D - cosentyx 21
This text simply states "Viewing window" and does not provide enough context to generate a useful description.*
Figure E - cosentyx 22
Figure F - cosentyx 23
Figure G - cosentyx 24
Figure H - cosentyx 25
Holding your COSENTYX Sensoready Pen: - cosentyx 26
Figure I - cosentyx 27
Figure J - cosentyx 28
Figure K - cosentyx 29
Figure L - cosentyx 30
Figure M - cosentyx 31
Figure 4: ASAS40 Responses in nr-axSpA1 Study Over Time up to Week 16 - cosentyx 32
The text shows a graph of the percentage of responders over time (in weeks) for three different treatments: Cosentyx 150 mg Load, Cosentyx 150 mg No Load, and Placebo. The graph shows that both Cosentyx treatments have a higher percentage of responders than the Placebo, and that the Load treatment appears to have a quicker and more significant effect than the No Load. No further information is available.*
PRINCIPAL DISPLAY PANEL NDC 0078-1056-97 Cosentyx® (secukinumab) Injection 75 mg/0.5 mL 1 Single-dose Prefilled Syringe For Subcutaneous Use Only Caution: Contains Natural Rubber Latex Which May Cause Allergic Reaction. ATTENTION: Dispense with enclosed Medication Guide. NOVARTIS - cosentyx 33
Cosentyx is an injectable medication for subcutaneous use for the treatment of plaque psoriasis. The medication significantly reduces inflammation, slows down joint damage, and improves symptoms associated with psoriasis. It is important to store this medication at a temperature between 2°C to 8°C and to discard the unused portion. The drug contains natural rubber latex which may cause an allergic reaction. Patient instructions and drug information are provided.*
Figure 1: Percent of Patients Achieving ACR 20 Responsea in PsA1 Study Through Week 24 - cosentyx 34
This text appears to be a chart or graph displaying the percentage of respondents, time in weeks, and treatment options (10mg Cosenly, Cosentyx 0mg, and placebo). It is not possible to determine the context or purpose of the chart from this limited information.*
Figure 2: ASAS20 Responses in all AS1 Study Patients Over Time Up to Week 16 - cosentyx 35
This appears to be a graph or chart showing the percentage of respondents in relation to weeks and treatment (Cosentyx 150mg and Placebo). Without further context, it is not possible to provide a more detailed or accurate description.*
Figure 3: ASAS20 Responses in all AS3 Study Patients Over Time Up to Week 16 - cosentyx 36
This appears to be a graph showing the percentage of respondents over time in weeks for different treatments, including Cosenlyx at 150 mg with IV loading and Coseniyx at 300 mg with IV loading, compared to a placebo. The graph shows that both doses of Cosenlyx have a higher percentage of respondents than the placebo.*
COSENTYX prefilled syringe parts (see Figure A): - cosentyx 37
This appears to be a description of a syringe. It includes features such as finger grips, a plunger, a view window, a needle cap, label and guard wings, and an expiration date label.*
Figure B - cosentyx 38
Figure C - cosentyx 39
Figure D - cosentyx 40
Figure E - cosentyx 41
Figure F - cosentyx 42
Figure G - cosentyx 43
Figure H - cosentyx 44
Figure I - cosentyx 45
Figure J - cosentyx 46
cosentyx 47
cosentyx 48
This data appears to be from a clinical trial comparing the effectiveness of a drug called Cosentyx with a placebo. The x-axis displays time in days, while the y-axis shows the number of patients at risk. The numbers below the x-axis, however, are not legible or recognizable, so it is not possible to provide further information.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.